Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Zytiga Forms Key Part of Cancer Strategy

412 views

Published on

Zytiga Forms Key Part of Cancer Strategy

  • Be the first to comment

  • Be the first to like this

Zytiga Forms Key Part of Cancer Strategy

  1. 1. Zytiga Forms Key Part of Cancer Strategy
  2. 2. Zytiga Forms Key Part of Cancer Strategy Over the course of his career as a biotechnology investor, Dr. Lindsay Rosenwald has helped to fund several groundbreaking treatments. At Cougar Biotechnology, Inc., which Dr. Lindsay Rosenwald co-founded, he helped to push the drug Zytiga through two stages of clinical trials.
  3. 3. Zytiga Forms Key Part of Cancer Strategy Cougar Biotechnology was bought out by Johnson & Johnson while Zytiga was still under development. The drug is now an important part of the company’s strategy in cancer therapeutics. Zytiga , which is approved to treat chemotherapy-naïve metastatic-castrationresistant prostate cancer and chemo-refractory metastaticcastration-resistant prostate cancer, accounts for nearly one-third of the market for drugs of its type in the United States.
  4. 4. Zytiga Forms Key Part of Cancer Strategy The need for drugs like Zytiga is growing, as well. Prostate cancer accounted for 14 percent of cancer diagnosed in men worldwide in 2008. The disease is primarily diagnosed in developed countries where Johnson & Johnson has experience in operating. Overall, cancer diagnoses are expected to grow significantly in the next several decades.

×